Global Non-Insulin Therapies for Diabetes Market Research Report 2024(Status and Outlook)
Report Overview
This report provides a deep insight into the global Non-Insulin Therapies for Diabetes market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Non-Insulin Therapies for Diabetes Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Non-Insulin Therapies for Diabetes market in any manner.
Global Non-Insulin Therapies for Diabetes Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
GSK
Eli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Pfizer
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
3SBio
Jiangsu Hengrui Medicine
Market Segmentation (by Type)
Alpha-glucosidase Inhibitors
Amylin Agonists
Biguanides
Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Glinides / Meglitinides
GLP-1 Analogs / GLP-1 Agonists
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Sulfonylureas
Thiazolidinediones
Others
by Application
Market Segmentation (by Application)
Monitoring
Diagnosis
Treatment
Others
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Non-Insulin Therapies for Diabetes Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
This report provides a deep insight into the global Non-Insulin Therapies for Diabetes market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Non-Insulin Therapies for Diabetes Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Non-Insulin Therapies for Diabetes market in any manner.
Global Non-Insulin Therapies for Diabetes Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
GSK
Eli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Pfizer
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
3SBio
Jiangsu Hengrui Medicine
Market Segmentation (by Type)
Alpha-glucosidase Inhibitors
Amylin Agonists
Biguanides
Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Glinides / Meglitinides
GLP-1 Analogs / GLP-1 Agonists
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Sulfonylureas
Thiazolidinediones
Others
by Application
Market Segmentation (by Application)
Monitoring
Diagnosis
Treatment
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Non-Insulin Therapies for Diabetes Market
- Overview of the regional outlook of the Non-Insulin Therapies for Diabetes Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Non-Insulin Therapies for Diabetes Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Non-Insulin Therapies for Diabetes
1.2 Key Market Segments
1.2.1 Non-Insulin Therapies for Diabetes Segment by Type
1.2.2 Non-Insulin Therapies for Diabetes Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NON-INSULIN THERAPIES FOR DIABETES MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Non-Insulin Therapies for Diabetes Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Non-Insulin Therapies for Diabetes Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NON-INSULIN THERAPIES FOR DIABETES MARKET COMPETITIVE LANDSCAPE
3.1 Global Non-Insulin Therapies for Diabetes Sales by Manufacturers (2019-2024)
3.2 Global Non-Insulin Therapies for Diabetes Revenue Market Share by Manufacturers (2019-2024)
3.3 Non-Insulin Therapies for Diabetes Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Non-Insulin Therapies for Diabetes Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Non-Insulin Therapies for Diabetes Sales Sites, Area Served, Product Type
3.6 Non-Insulin Therapies for Diabetes Market Competitive Situation and Trends
3.6.1 Non-Insulin Therapies for Diabetes Market Concentration Rate
3.6.2 Global 5 and 10 Largest Non-Insulin Therapies for Diabetes Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NON-INSULIN THERAPIES FOR DIABETES INDUSTRY CHAIN ANALYSIS
4.1 Non-Insulin Therapies for Diabetes Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NON-INSULIN THERAPIES FOR DIABETES MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 NON-INSULIN THERAPIES FOR DIABETES MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Non-Insulin Therapies for Diabetes Sales Market Share by Type (2019-2024)
6.3 Global Non-Insulin Therapies for Diabetes Market Size Market Share by Type (2019-2024)
6.4 Global Non-Insulin Therapies for Diabetes Price by Type (2019-2024)
7 NON-INSULIN THERAPIES FOR DIABETES MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Non-Insulin Therapies for Diabetes Market Sales by Application (2019-2024)
7.3 Global Non-Insulin Therapies for Diabetes Market Size (M USD) by Application (2019-2024)
7.4 Global Non-Insulin Therapies for Diabetes Sales Growth Rate by Application (2019-2024)
8 NON-INSULIN THERAPIES FOR DIABETES MARKET SEGMENTATION BY REGION
8.1 Global Non-Insulin Therapies for Diabetes Sales by Region
8.1.1 Global Non-Insulin Therapies for Diabetes Sales by Region
8.1.2 Global Non-Insulin Therapies for Diabetes Sales Market Share by Region
8.2 North America
8.2.1 North America Non-Insulin Therapies for Diabetes Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Non-Insulin Therapies for Diabetes Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Non-Insulin Therapies for Diabetes Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Non-Insulin Therapies for Diabetes Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Non-Insulin Therapies for Diabetes Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 GSK
9.1.1 GSK Non-Insulin Therapies for Diabetes Basic Information
9.1.2 GSK Non-Insulin Therapies for Diabetes Product Overview
9.1.3 GSK Non-Insulin Therapies for Diabetes Product Market Performance
9.1.4 GSK Business Overview
9.1.5 GSK Non-Insulin Therapies for Diabetes SWOT Analysis
9.1.6 GSK Recent Developments
9.2 Eli Lilly
9.2.1 Eli Lilly Non-Insulin Therapies for Diabetes Basic Information
9.2.2 Eli Lilly Non-Insulin Therapies for Diabetes Product Overview
9.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Product Market Performance
9.2.4 Eli Lilly Business Overview
9.2.5 Eli Lilly Non-Insulin Therapies for Diabetes SWOT Analysis
9.2.6 Eli Lilly Recent Developments
9.3 Sumitomo Dainippon Pharma
9.3.1 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Basic Information
9.3.2 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product Overview
9.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product Market Performance
9.3.4 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes SWOT Analysis
9.3.5 Sumitomo Dainippon Pharma Business Overview
9.3.6 Sumitomo Dainippon Pharma Recent Developments
9.4 Intarcia Therapeutics
9.4.1 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Basic Information
9.4.2 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product Overview
9.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product Market Performance
9.4.4 Intarcia Therapeutics Business Overview
9.4.5 Intarcia Therapeutics Recent Developments
9.5 Servier
9.5.1 Servier Non-Insulin Therapies for Diabetes Basic Information
9.5.2 Servier Non-Insulin Therapies for Diabetes Product Overview
9.5.3 Servier Non-Insulin Therapies for Diabetes Product Market Performance
9.5.4 Servier Business Overview
9.5.5 Servier Recent Developments
9.6 Pfizer
9.6.1 Pfizer Non-Insulin Therapies for Diabetes Basic Information
9.6.2 Pfizer Non-Insulin Therapies for Diabetes Product Overview
9.6.3 Pfizer Non-Insulin Therapies for Diabetes Product Market Performance
9.6.4 Pfizer Business Overview
9.6.5 Pfizer Recent Developments
9.7 Merck
9.7.1 Merck Non-Insulin Therapies for Diabetes Basic Information
9.7.2 Merck Non-Insulin Therapies for Diabetes Product Overview
9.7.3 Merck Non-Insulin Therapies for Diabetes Product Market Performance
9.7.4 Merck Business Overview
9.7.5 Merck Recent Developments
9.8 Dong-A Pharmaceutical
9.8.1 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Basic Information
9.8.2 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product Overview
9.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product Market Performance
9.8.4 Dong-A Pharmaceutical Business Overview
9.8.5 Dong-A Pharmaceutical Recent Developments
9.9 Luye Pharma Group
9.9.1 Luye Pharma Group Non-Insulin Therapies for Diabetes Basic Information
9.9.2 Luye Pharma Group Non-Insulin Therapies for Diabetes Product Overview
9.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Product Market Performance
9.9.4 Luye Pharma Group Business Overview
9.9.5 Luye Pharma Group Recent Developments
9.10 Eurofarma
9.10.1 Eurofarma Non-Insulin Therapies for Diabetes Basic Information
9.10.2 Eurofarma Non-Insulin Therapies for Diabetes Product Overview
9.10.3 Eurofarma Non-Insulin Therapies for Diabetes Product Market Performance
9.10.4 Eurofarma Business Overview
9.10.5 Eurofarma Recent Developments
9.11 Geropharm
9.11.1 Geropharm Non-Insulin Therapies for Diabetes Basic Information
9.11.2 Geropharm Non-Insulin Therapies for Diabetes Product Overview
9.11.3 Geropharm Non-Insulin Therapies for Diabetes Product Market Performance
9.11.4 Geropharm Business Overview
9.11.5 Geropharm Recent Developments
9.12 Alkem Labs
9.12.1 Alkem Labs Non-Insulin Therapies for Diabetes Basic Information
9.12.2 Alkem Labs Non-Insulin Therapies for Diabetes Product Overview
9.12.3 Alkem Labs Non-Insulin Therapies for Diabetes Product Market Performance
9.12.4 Alkem Labs Business Overview
9.12.5 Alkem Labs Recent Developments
9.13 SatRx
9.13.1 SatRx Non-Insulin Therapies for Diabetes Basic Information
9.13.2 SatRx Non-Insulin Therapies for Diabetes Product Overview
9.13.3 SatRx Non-Insulin Therapies for Diabetes Product Market Performance
9.13.4 SatRx Business Overview
9.13.5 SatRx Recent Developments
9.14 Jiangsu Hansoh Pharmaceutical
9.14.1 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Basic Information
9.14.2 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product Overview
9.14.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product Market Performance
9.14.4 Jiangsu Hansoh Pharmaceutical Business Overview
9.14.5 Jiangsu Hansoh Pharmaceutical Recent Developments
9.15 Novo Nordisk
9.15.1 Novo Nordisk Non-Insulin Therapies for Diabetes Basic Information
9.15.2 Novo Nordisk Non-Insulin Therapies for Diabetes Product Overview
9.15.3 Novo Nordisk Non-Insulin Therapies for Diabetes Product Market Performance
9.15.4 Novo Nordisk Business Overview
9.15.5 Novo Nordisk Recent Developments
9.16 Emisphere
9.16.1 Emisphere Non-Insulin Therapies for Diabetes Basic Information
9.16.2 Emisphere Non-Insulin Therapies for Diabetes Product Overview
9.16.3 Emisphere Non-Insulin Therapies for Diabetes Product Market Performance
9.16.4 Emisphere Business Overview
9.16.5 Emisphere Recent Developments
9.17 Uni-Bio Science Group
9.17.1 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Basic Information
9.17.2 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product Overview
9.17.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product Market Performance
9.17.4 Uni-Bio Science Group Business Overview
9.17.5 Uni-Bio Science Group Recent Developments
9.18 Takeda
9.18.1 Takeda Non-Insulin Therapies for Diabetes Basic Information
9.18.2 Takeda Non-Insulin Therapies for Diabetes Product Overview
9.18.3 Takeda Non-Insulin Therapies for Diabetes Product Market Performance
9.18.4 Takeda Business Overview
9.18.5 Takeda Recent Developments
9.19 3SBio
9.19.1 3SBio Non-Insulin Therapies for Diabetes Basic Information
9.19.2 3SBio Non-Insulin Therapies for Diabetes Product Overview
9.19.3 3SBio Non-Insulin Therapies for Diabetes Product Market Performance
9.19.4 3SBio Business Overview
9.19.5 3SBio Recent Developments
9.20 Jiangsu Hengrui Medicine
9.20.1 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Basic Information
9.20.2 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product Overview
9.20.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product Market Performance
9.20.4 Jiangsu Hengrui Medicine Business Overview
9.20.5 Jiangsu Hengrui Medicine Recent Developments
10 NON-INSULIN THERAPIES FOR DIABETES MARKET FORECAST BY REGION
10.1 Global Non-Insulin Therapies for Diabetes Market Size Forecast
10.2 Global Non-Insulin Therapies for Diabetes Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Non-Insulin Therapies for Diabetes Market Size Forecast by Country
10.2.3 Asia Pacific Non-Insulin Therapies for Diabetes Market Size Forecast by Region
10.2.4 South America Non-Insulin Therapies for Diabetes Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Non-Insulin Therapies for Diabetes by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Non-Insulin Therapies for Diabetes Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Non-Insulin Therapies for Diabetes by Type (2025-2030)
11.1.2 Global Non-Insulin Therapies for Diabetes Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Non-Insulin Therapies for Diabetes by Type (2025-2030)
11.2 Global Non-Insulin Therapies for Diabetes Market Forecast by Application (2025-2030)
11.2.1 Global Non-Insulin Therapies for Diabetes Sales (K Units) Forecast by Application
11.2.2 Global Non-Insulin Therapies for Diabetes Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Non-Insulin Therapies for Diabetes
1.2 Key Market Segments
1.2.1 Non-Insulin Therapies for Diabetes Segment by Type
1.2.2 Non-Insulin Therapies for Diabetes Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NON-INSULIN THERAPIES FOR DIABETES MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Non-Insulin Therapies for Diabetes Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Non-Insulin Therapies for Diabetes Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NON-INSULIN THERAPIES FOR DIABETES MARKET COMPETITIVE LANDSCAPE
3.1 Global Non-Insulin Therapies for Diabetes Sales by Manufacturers (2019-2024)
3.2 Global Non-Insulin Therapies for Diabetes Revenue Market Share by Manufacturers (2019-2024)
3.3 Non-Insulin Therapies for Diabetes Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Non-Insulin Therapies for Diabetes Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Non-Insulin Therapies for Diabetes Sales Sites, Area Served, Product Type
3.6 Non-Insulin Therapies for Diabetes Market Competitive Situation and Trends
3.6.1 Non-Insulin Therapies for Diabetes Market Concentration Rate
3.6.2 Global 5 and 10 Largest Non-Insulin Therapies for Diabetes Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NON-INSULIN THERAPIES FOR DIABETES INDUSTRY CHAIN ANALYSIS
4.1 Non-Insulin Therapies for Diabetes Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NON-INSULIN THERAPIES FOR DIABETES MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 NON-INSULIN THERAPIES FOR DIABETES MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Non-Insulin Therapies for Diabetes Sales Market Share by Type (2019-2024)
6.3 Global Non-Insulin Therapies for Diabetes Market Size Market Share by Type (2019-2024)
6.4 Global Non-Insulin Therapies for Diabetes Price by Type (2019-2024)
7 NON-INSULIN THERAPIES FOR DIABETES MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Non-Insulin Therapies for Diabetes Market Sales by Application (2019-2024)
7.3 Global Non-Insulin Therapies for Diabetes Market Size (M USD) by Application (2019-2024)
7.4 Global Non-Insulin Therapies for Diabetes Sales Growth Rate by Application (2019-2024)
8 NON-INSULIN THERAPIES FOR DIABETES MARKET SEGMENTATION BY REGION
8.1 Global Non-Insulin Therapies for Diabetes Sales by Region
8.1.1 Global Non-Insulin Therapies for Diabetes Sales by Region
8.1.2 Global Non-Insulin Therapies for Diabetes Sales Market Share by Region
8.2 North America
8.2.1 North America Non-Insulin Therapies for Diabetes Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Non-Insulin Therapies for Diabetes Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Non-Insulin Therapies for Diabetes Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Non-Insulin Therapies for Diabetes Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Non-Insulin Therapies for Diabetes Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 GSK
9.1.1 GSK Non-Insulin Therapies for Diabetes Basic Information
9.1.2 GSK Non-Insulin Therapies for Diabetes Product Overview
9.1.3 GSK Non-Insulin Therapies for Diabetes Product Market Performance
9.1.4 GSK Business Overview
9.1.5 GSK Non-Insulin Therapies for Diabetes SWOT Analysis
9.1.6 GSK Recent Developments
9.2 Eli Lilly
9.2.1 Eli Lilly Non-Insulin Therapies for Diabetes Basic Information
9.2.2 Eli Lilly Non-Insulin Therapies for Diabetes Product Overview
9.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Product Market Performance
9.2.4 Eli Lilly Business Overview
9.2.5 Eli Lilly Non-Insulin Therapies for Diabetes SWOT Analysis
9.2.6 Eli Lilly Recent Developments
9.3 Sumitomo Dainippon Pharma
9.3.1 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Basic Information
9.3.2 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product Overview
9.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product Market Performance
9.3.4 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes SWOT Analysis
9.3.5 Sumitomo Dainippon Pharma Business Overview
9.3.6 Sumitomo Dainippon Pharma Recent Developments
9.4 Intarcia Therapeutics
9.4.1 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Basic Information
9.4.2 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product Overview
9.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product Market Performance
9.4.4 Intarcia Therapeutics Business Overview
9.4.5 Intarcia Therapeutics Recent Developments
9.5 Servier
9.5.1 Servier Non-Insulin Therapies for Diabetes Basic Information
9.5.2 Servier Non-Insulin Therapies for Diabetes Product Overview
9.5.3 Servier Non-Insulin Therapies for Diabetes Product Market Performance
9.5.4 Servier Business Overview
9.5.5 Servier Recent Developments
9.6 Pfizer
9.6.1 Pfizer Non-Insulin Therapies for Diabetes Basic Information
9.6.2 Pfizer Non-Insulin Therapies for Diabetes Product Overview
9.6.3 Pfizer Non-Insulin Therapies for Diabetes Product Market Performance
9.6.4 Pfizer Business Overview
9.6.5 Pfizer Recent Developments
9.7 Merck
9.7.1 Merck Non-Insulin Therapies for Diabetes Basic Information
9.7.2 Merck Non-Insulin Therapies for Diabetes Product Overview
9.7.3 Merck Non-Insulin Therapies for Diabetes Product Market Performance
9.7.4 Merck Business Overview
9.7.5 Merck Recent Developments
9.8 Dong-A Pharmaceutical
9.8.1 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Basic Information
9.8.2 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product Overview
9.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product Market Performance
9.8.4 Dong-A Pharmaceutical Business Overview
9.8.5 Dong-A Pharmaceutical Recent Developments
9.9 Luye Pharma Group
9.9.1 Luye Pharma Group Non-Insulin Therapies for Diabetes Basic Information
9.9.2 Luye Pharma Group Non-Insulin Therapies for Diabetes Product Overview
9.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Product Market Performance
9.9.4 Luye Pharma Group Business Overview
9.9.5 Luye Pharma Group Recent Developments
9.10 Eurofarma
9.10.1 Eurofarma Non-Insulin Therapies for Diabetes Basic Information
9.10.2 Eurofarma Non-Insulin Therapies for Diabetes Product Overview
9.10.3 Eurofarma Non-Insulin Therapies for Diabetes Product Market Performance
9.10.4 Eurofarma Business Overview
9.10.5 Eurofarma Recent Developments
9.11 Geropharm
9.11.1 Geropharm Non-Insulin Therapies for Diabetes Basic Information
9.11.2 Geropharm Non-Insulin Therapies for Diabetes Product Overview
9.11.3 Geropharm Non-Insulin Therapies for Diabetes Product Market Performance
9.11.4 Geropharm Business Overview
9.11.5 Geropharm Recent Developments
9.12 Alkem Labs
9.12.1 Alkem Labs Non-Insulin Therapies for Diabetes Basic Information
9.12.2 Alkem Labs Non-Insulin Therapies for Diabetes Product Overview
9.12.3 Alkem Labs Non-Insulin Therapies for Diabetes Product Market Performance
9.12.4 Alkem Labs Business Overview
9.12.5 Alkem Labs Recent Developments
9.13 SatRx
9.13.1 SatRx Non-Insulin Therapies for Diabetes Basic Information
9.13.2 SatRx Non-Insulin Therapies for Diabetes Product Overview
9.13.3 SatRx Non-Insulin Therapies for Diabetes Product Market Performance
9.13.4 SatRx Business Overview
9.13.5 SatRx Recent Developments
9.14 Jiangsu Hansoh Pharmaceutical
9.14.1 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Basic Information
9.14.2 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product Overview
9.14.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product Market Performance
9.14.4 Jiangsu Hansoh Pharmaceutical Business Overview
9.14.5 Jiangsu Hansoh Pharmaceutical Recent Developments
9.15 Novo Nordisk
9.15.1 Novo Nordisk Non-Insulin Therapies for Diabetes Basic Information
9.15.2 Novo Nordisk Non-Insulin Therapies for Diabetes Product Overview
9.15.3 Novo Nordisk Non-Insulin Therapies for Diabetes Product Market Performance
9.15.4 Novo Nordisk Business Overview
9.15.5 Novo Nordisk Recent Developments
9.16 Emisphere
9.16.1 Emisphere Non-Insulin Therapies for Diabetes Basic Information
9.16.2 Emisphere Non-Insulin Therapies for Diabetes Product Overview
9.16.3 Emisphere Non-Insulin Therapies for Diabetes Product Market Performance
9.16.4 Emisphere Business Overview
9.16.5 Emisphere Recent Developments
9.17 Uni-Bio Science Group
9.17.1 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Basic Information
9.17.2 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product Overview
9.17.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product Market Performance
9.17.4 Uni-Bio Science Group Business Overview
9.17.5 Uni-Bio Science Group Recent Developments
9.18 Takeda
9.18.1 Takeda Non-Insulin Therapies for Diabetes Basic Information
9.18.2 Takeda Non-Insulin Therapies for Diabetes Product Overview
9.18.3 Takeda Non-Insulin Therapies for Diabetes Product Market Performance
9.18.4 Takeda Business Overview
9.18.5 Takeda Recent Developments
9.19 3SBio
9.19.1 3SBio Non-Insulin Therapies for Diabetes Basic Information
9.19.2 3SBio Non-Insulin Therapies for Diabetes Product Overview
9.19.3 3SBio Non-Insulin Therapies for Diabetes Product Market Performance
9.19.4 3SBio Business Overview
9.19.5 3SBio Recent Developments
9.20 Jiangsu Hengrui Medicine
9.20.1 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Basic Information
9.20.2 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product Overview
9.20.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product Market Performance
9.20.4 Jiangsu Hengrui Medicine Business Overview
9.20.5 Jiangsu Hengrui Medicine Recent Developments
10 NON-INSULIN THERAPIES FOR DIABETES MARKET FORECAST BY REGION
10.1 Global Non-Insulin Therapies for Diabetes Market Size Forecast
10.2 Global Non-Insulin Therapies for Diabetes Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Non-Insulin Therapies for Diabetes Market Size Forecast by Country
10.2.3 Asia Pacific Non-Insulin Therapies for Diabetes Market Size Forecast by Region
10.2.4 South America Non-Insulin Therapies for Diabetes Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Non-Insulin Therapies for Diabetes by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Non-Insulin Therapies for Diabetes Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Non-Insulin Therapies for Diabetes by Type (2025-2030)
11.1.2 Global Non-Insulin Therapies for Diabetes Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Non-Insulin Therapies for Diabetes by Type (2025-2030)
11.2 Global Non-Insulin Therapies for Diabetes Market Forecast by Application (2025-2030)
11.2.1 Global Non-Insulin Therapies for Diabetes Sales (K Units) Forecast by Application
11.2.2 Global Non-Insulin Therapies for Diabetes Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Non-Insulin Therapies for Diabetes Market Size Comparison by Region (M USD)
Table 5. Global Non-Insulin Therapies for Diabetes Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Non-Insulin Therapies for Diabetes Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Non-Insulin Therapies for Diabetes Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Non-Insulin Therapies for Diabetes Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2022)
Table 10. Global Market Non-Insulin Therapies for Diabetes Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Non-Insulin Therapies for Diabetes Sales Sites and Area Served
Table 12. Manufacturers Non-Insulin Therapies for Diabetes Product Type
Table 13. Global Non-Insulin Therapies for Diabetes Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Non-Insulin Therapies for Diabetes
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Non-Insulin Therapies for Diabetes Market Challenges
Table 22. Global Non-Insulin Therapies for Diabetes Sales by Type (K Units)
Table 23. Global Non-Insulin Therapies for Diabetes Market Size by Type (M USD)
Table 24. Global Non-Insulin Therapies for Diabetes Sales (K Units) by Type (2019-2024)
Table 25. Global Non-Insulin Therapies for Diabetes Sales Market Share by Type (2019-2024)
Table 26. Global Non-Insulin Therapies for Diabetes Market Size (M USD) by Type (2019-2024)
Table 27. Global Non-Insulin Therapies for Diabetes Market Size Share by Type (2019-2024)
Table 28. Global Non-Insulin Therapies for Diabetes Price (USD/Unit) by Type (2019-2024)
Table 29. Global Non-Insulin Therapies for Diabetes Sales (K Units) by Application
Table 30. Global Non-Insulin Therapies for Diabetes Market Size by Application
Table 31. Global Non-Insulin Therapies for Diabetes Sales by Application (2019-2024) & (K Units)
Table 32. Global Non-Insulin Therapies for Diabetes Sales Market Share by Application (2019-2024)
Table 33. Global Non-Insulin Therapies for Diabetes Sales by Application (2019-2024) & (M USD)
Table 34. Global Non-Insulin Therapies for Diabetes Market Share by Application (2019-2024)
Table 35. Global Non-Insulin Therapies for Diabetes Sales Growth Rate by Application (2019-2024)
Table 36. Global Non-Insulin Therapies for Diabetes Sales by Region (2019-2024) & (K Units)
Table 37. Global Non-Insulin Therapies for Diabetes Sales Market Share by Region (2019-2024)
Table 38. North America Non-Insulin Therapies for Diabetes Sales by Country (2019-2024) & (K Units)
Table 39. Europe Non-Insulin Therapies for Diabetes Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Non-Insulin Therapies for Diabetes Sales by Region (2019-2024) & (K Units)
Table 41. South America Non-Insulin Therapies for Diabetes Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Non-Insulin Therapies for Diabetes Sales by Region (2019-2024) & (K Units)
Table 43. GSK Non-Insulin Therapies for Diabetes Basic Information
Table 44. GSK Non-Insulin Therapies for Diabetes Product Overview
Table 45. GSK Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. GSK Business Overview
Table 47. GSK Non-Insulin Therapies for Diabetes SWOT Analysis
Table 48. GSK Recent Developments
Table 49. Eli Lilly Non-Insulin Therapies for Diabetes Basic Information
Table 50. Eli Lilly Non-Insulin Therapies for Diabetes Product Overview
Table 51. Eli Lilly Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Eli Lilly Business Overview
Table 53. Eli Lilly Non-Insulin Therapies for Diabetes SWOT Analysis
Table 54. Eli Lilly Recent Developments
Table 55. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Basic Information
Table 56. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product Overview
Table 57. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes SWOT Analysis
Table 59. Sumitomo Dainippon Pharma Business Overview
Table 60. Sumitomo Dainippon Pharma Recent Developments
Table 61. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Basic Information
Table 62. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product Overview
Table 63. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Intarcia Therapeutics Business Overview
Table 65. Intarcia Therapeutics Recent Developments
Table 66. Servier Non-Insulin Therapies for Diabetes Basic Information
Table 67. Servier Non-Insulin Therapies for Diabetes Product Overview
Table 68. Servier Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Servier Business Overview
Table 70. Servier Recent Developments
Table 71. Pfizer Non-Insulin Therapies for Diabetes Basic Information
Table 72. Pfizer Non-Insulin Therapies for Diabetes Product Overview
Table 73. Pfizer Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Pfizer Business Overview
Table 75. Pfizer Recent Developments
Table 76. Merck Non-Insulin Therapies for Diabetes Basic Information
Table 77. Merck Non-Insulin Therapies for Diabetes Product Overview
Table 78. Merck Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Merck Business Overview
Table 80. Merck Recent Developments
Table 81. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Basic Information
Table 82. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product Overview
Table 83. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Dong-A Pharmaceutical Business Overview
Table 85. Dong-A Pharmaceutical Recent Developments
Table 86. Luye Pharma Group Non-Insulin Therapies for Diabetes Basic Information
Table 87. Luye Pharma Group Non-Insulin Therapies for Diabetes Product Overview
Table 88. Luye Pharma Group Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Luye Pharma Group Business Overview
Table 90. Luye Pharma Group Recent Developments
Table 91. Eurofarma Non-Insulin Therapies for Diabetes Basic Information
Table 92. Eurofarma Non-Insulin Therapies for Diabetes Product Overview
Table 93. Eurofarma Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Eurofarma Business Overview
Table 95. Eurofarma Recent Developments
Table 96. Geropharm Non-Insulin Therapies for Diabetes Basic Information
Table 97. Geropharm Non-Insulin Therapies for Diabetes Product Overview
Table 98. Geropharm Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Geropharm Business Overview
Table 100. Geropharm Recent Developments
Table 101. Alkem Labs Non-Insulin Therapies for Diabetes Basic Information
Table 102. Alkem Labs Non-Insulin Therapies for Diabetes Product Overview
Table 103. Alkem Labs Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Alkem Labs Business Overview
Table 105. Alkem Labs Recent Developments
Table 106. SatRx Non-Insulin Therapies for Diabetes Basic Information
Table 107. SatRx Non-Insulin Therapies for Diabetes Product Overview
Table 108. SatRx Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. SatRx Business Overview
Table 110. SatRx Recent Developments
Table 111. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Basic Information
Table 112. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product Overview
Table 113. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Jiangsu Hansoh Pharmaceutical Business Overview
Table 115. Jiangsu Hansoh Pharmaceutical Recent Developments
Table 116. Novo Nordisk Non-Insulin Therapies for Diabetes Basic Information
Table 117. Novo Nordisk Non-Insulin Therapies for Diabetes Product Overview
Table 118. Novo Nordisk Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Novo Nordisk Business Overview
Table 120. Novo Nordisk Recent Developments
Table 121. Emisphere Non-Insulin Therapies for Diabetes Basic Information
Table 122. Emisphere Non-Insulin Therapies for Diabetes Product Overview
Table 123. Emisphere Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Emisphere Business Overview
Table 125. Emisphere Recent Developments
Table 126. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Basic Information
Table 127. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product Overview
Table 128. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Uni-Bio Science Group Business Overview
Table 130. Uni-Bio Science Group Recent Developments
Table 131. Takeda Non-Insulin Therapies for Diabetes Basic Information
Table 132. Takeda Non-Insulin Therapies for Diabetes Product Overview
Table 133. Takeda Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Takeda Business Overview
Table 135. Takeda Recent Developments
Table 136. 3SBio Non-Insulin Therapies for Diabetes Basic Information
Table 137. 3SBio Non-Insulin Therapies for Diabetes Product Overview
Table 138. 3SBio Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 139. 3SBio Business Overview
Table 140. 3SBio Recent Developments
Table 141. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Basic Information
Table 142. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product Overview
Table 143. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 144. Jiangsu Hengrui Medicine Business Overview
Table 145. Jiangsu Hengrui Medicine Recent Developments
Table 146. Global Non-Insulin Therapies for Diabetes Sales Forecast by Region (2025-2030) & (K Units)
Table 147. Global Non-Insulin Therapies for Diabetes Market Size Forecast by Region (2025-2030) & (M USD)
Table 148. North America Non-Insulin Therapies for Diabetes Sales Forecast by Country (2025-2030) & (K Units)
Table 149. North America Non-Insulin Therapies for Diabetes Market Size Forecast by Country (2025-2030) & (M USD)
Table 150. Europe Non-Insulin Therapies for Diabetes Sales Forecast by Country (2025-2030) & (K Units)
Table 151. Europe Non-Insulin Therapies for Diabetes Market Size Forecast by Country (2025-2030) & (M USD)
Table 152. Asia Pacific Non-Insulin Therapies for Diabetes Sales Forecast by Region (2025-2030) & (K Units)
Table 153. Asia Pacific Non-Insulin Therapies for Diabetes Market Size Forecast by Region (2025-2030) & (M USD)
Table 154. South America Non-Insulin Therapies for Diabetes Sales Forecast by Country (2025-2030) & (K Units)
Table 155. South America Non-Insulin Therapies for Diabetes Market Size Forecast by Country (2025-2030) & (M USD)
Table 156. Middle East and Africa Non-Insulin Therapies for Diabetes Consumption Forecast by Country (2025-2030) & (Units)
Table 157. Middle East and Africa Non-Insulin Therapies for Diabetes Market Size Forecast by Country (2025-2030) & (M USD)
Table 158. Global Non-Insulin Therapies for Diabetes Sales Forecast by Type (2025-2030) & (K Units)
Table 159. Global Non-Insulin Therapies for Diabetes Market Size Forecast by Type (2025-2030) & (M USD)
Table 160. Global Non-Insulin Therapies for Diabetes Price Forecast by Type (2025-2030) & (USD/Unit)
Table 161. Global Non-Insulin Therapies for Diabetes Sales (K Units) Forecast by Application (2025-2030)
Table 162. Global Non-Insulin Therapies for Diabetes Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Non-Insulin Therapies for Diabetes Market Size Comparison by Region (M USD)
Table 5. Global Non-Insulin Therapies for Diabetes Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Non-Insulin Therapies for Diabetes Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Non-Insulin Therapies for Diabetes Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Non-Insulin Therapies for Diabetes Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2022)
Table 10. Global Market Non-Insulin Therapies for Diabetes Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Non-Insulin Therapies for Diabetes Sales Sites and Area Served
Table 12. Manufacturers Non-Insulin Therapies for Diabetes Product Type
Table 13. Global Non-Insulin Therapies for Diabetes Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Non-Insulin Therapies for Diabetes
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Non-Insulin Therapies for Diabetes Market Challenges
Table 22. Global Non-Insulin Therapies for Diabetes Sales by Type (K Units)
Table 23. Global Non-Insulin Therapies for Diabetes Market Size by Type (M USD)
Table 24. Global Non-Insulin Therapies for Diabetes Sales (K Units) by Type (2019-2024)
Table 25. Global Non-Insulin Therapies for Diabetes Sales Market Share by Type (2019-2024)
Table 26. Global Non-Insulin Therapies for Diabetes Market Size (M USD) by Type (2019-2024)
Table 27. Global Non-Insulin Therapies for Diabetes Market Size Share by Type (2019-2024)
Table 28. Global Non-Insulin Therapies for Diabetes Price (USD/Unit) by Type (2019-2024)
Table 29. Global Non-Insulin Therapies for Diabetes Sales (K Units) by Application
Table 30. Global Non-Insulin Therapies for Diabetes Market Size by Application
Table 31. Global Non-Insulin Therapies for Diabetes Sales by Application (2019-2024) & (K Units)
Table 32. Global Non-Insulin Therapies for Diabetes Sales Market Share by Application (2019-2024)
Table 33. Global Non-Insulin Therapies for Diabetes Sales by Application (2019-2024) & (M USD)
Table 34. Global Non-Insulin Therapies for Diabetes Market Share by Application (2019-2024)
Table 35. Global Non-Insulin Therapies for Diabetes Sales Growth Rate by Application (2019-2024)
Table 36. Global Non-Insulin Therapies for Diabetes Sales by Region (2019-2024) & (K Units)
Table 37. Global Non-Insulin Therapies for Diabetes Sales Market Share by Region (2019-2024)
Table 38. North America Non-Insulin Therapies for Diabetes Sales by Country (2019-2024) & (K Units)
Table 39. Europe Non-Insulin Therapies for Diabetes Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Non-Insulin Therapies for Diabetes Sales by Region (2019-2024) & (K Units)
Table 41. South America Non-Insulin Therapies for Diabetes Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Non-Insulin Therapies for Diabetes Sales by Region (2019-2024) & (K Units)
Table 43. GSK Non-Insulin Therapies for Diabetes Basic Information
Table 44. GSK Non-Insulin Therapies for Diabetes Product Overview
Table 45. GSK Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. GSK Business Overview
Table 47. GSK Non-Insulin Therapies for Diabetes SWOT Analysis
Table 48. GSK Recent Developments
Table 49. Eli Lilly Non-Insulin Therapies for Diabetes Basic Information
Table 50. Eli Lilly Non-Insulin Therapies for Diabetes Product Overview
Table 51. Eli Lilly Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Eli Lilly Business Overview
Table 53. Eli Lilly Non-Insulin Therapies for Diabetes SWOT Analysis
Table 54. Eli Lilly Recent Developments
Table 55. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Basic Information
Table 56. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product Overview
Table 57. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes SWOT Analysis
Table 59. Sumitomo Dainippon Pharma Business Overview
Table 60. Sumitomo Dainippon Pharma Recent Developments
Table 61. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Basic Information
Table 62. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product Overview
Table 63. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Intarcia Therapeutics Business Overview
Table 65. Intarcia Therapeutics Recent Developments
Table 66. Servier Non-Insulin Therapies for Diabetes Basic Information
Table 67. Servier Non-Insulin Therapies for Diabetes Product Overview
Table 68. Servier Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Servier Business Overview
Table 70. Servier Recent Developments
Table 71. Pfizer Non-Insulin Therapies for Diabetes Basic Information
Table 72. Pfizer Non-Insulin Therapies for Diabetes Product Overview
Table 73. Pfizer Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Pfizer Business Overview
Table 75. Pfizer Recent Developments
Table 76. Merck Non-Insulin Therapies for Diabetes Basic Information
Table 77. Merck Non-Insulin Therapies for Diabetes Product Overview
Table 78. Merck Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Merck Business Overview
Table 80. Merck Recent Developments
Table 81. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Basic Information
Table 82. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product Overview
Table 83. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Dong-A Pharmaceutical Business Overview
Table 85. Dong-A Pharmaceutical Recent Developments
Table 86. Luye Pharma Group Non-Insulin Therapies for Diabetes Basic Information
Table 87. Luye Pharma Group Non-Insulin Therapies for Diabetes Product Overview
Table 88. Luye Pharma Group Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Luye Pharma Group Business Overview
Table 90. Luye Pharma Group Recent Developments
Table 91. Eurofarma Non-Insulin Therapies for Diabetes Basic Information
Table 92. Eurofarma Non-Insulin Therapies for Diabetes Product Overview
Table 93. Eurofarma Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Eurofarma Business Overview
Table 95. Eurofarma Recent Developments
Table 96. Geropharm Non-Insulin Therapies for Diabetes Basic Information
Table 97. Geropharm Non-Insulin Therapies for Diabetes Product Overview
Table 98. Geropharm Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Geropharm Business Overview
Table 100. Geropharm Recent Developments
Table 101. Alkem Labs Non-Insulin Therapies for Diabetes Basic Information
Table 102. Alkem Labs Non-Insulin Therapies for Diabetes Product Overview
Table 103. Alkem Labs Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Alkem Labs Business Overview
Table 105. Alkem Labs Recent Developments
Table 106. SatRx Non-Insulin Therapies for Diabetes Basic Information
Table 107. SatRx Non-Insulin Therapies for Diabetes Product Overview
Table 108. SatRx Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. SatRx Business Overview
Table 110. SatRx Recent Developments
Table 111. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Basic Information
Table 112. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product Overview
Table 113. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Jiangsu Hansoh Pharmaceutical Business Overview
Table 115. Jiangsu Hansoh Pharmaceutical Recent Developments
Table 116. Novo Nordisk Non-Insulin Therapies for Diabetes Basic Information
Table 117. Novo Nordisk Non-Insulin Therapies for Diabetes Product Overview
Table 118. Novo Nordisk Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Novo Nordisk Business Overview
Table 120. Novo Nordisk Recent Developments
Table 121. Emisphere Non-Insulin Therapies for Diabetes Basic Information
Table 122. Emisphere Non-Insulin Therapies for Diabetes Product Overview
Table 123. Emisphere Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Emisphere Business Overview
Table 125. Emisphere Recent Developments
Table 126. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Basic Information
Table 127. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product Overview
Table 128. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Uni-Bio Science Group Business Overview
Table 130. Uni-Bio Science Group Recent Developments
Table 131. Takeda Non-Insulin Therapies for Diabetes Basic Information
Table 132. Takeda Non-Insulin Therapies for Diabetes Product Overview
Table 133. Takeda Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Takeda Business Overview
Table 135. Takeda Recent Developments
Table 136. 3SBio Non-Insulin Therapies for Diabetes Basic Information
Table 137. 3SBio Non-Insulin Therapies for Diabetes Product Overview
Table 138. 3SBio Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 139. 3SBio Business Overview
Table 140. 3SBio Recent Developments
Table 141. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Basic Information
Table 142. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product Overview
Table 143. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 144. Jiangsu Hengrui Medicine Business Overview
Table 145. Jiangsu Hengrui Medicine Recent Developments
Table 146. Global Non-Insulin Therapies for Diabetes Sales Forecast by Region (2025-2030) & (K Units)
Table 147. Global Non-Insulin Therapies for Diabetes Market Size Forecast by Region (2025-2030) & (M USD)
Table 148. North America Non-Insulin Therapies for Diabetes Sales Forecast by Country (2025-2030) & (K Units)
Table 149. North America Non-Insulin Therapies for Diabetes Market Size Forecast by Country (2025-2030) & (M USD)
Table 150. Europe Non-Insulin Therapies for Diabetes Sales Forecast by Country (2025-2030) & (K Units)
Table 151. Europe Non-Insulin Therapies for Diabetes Market Size Forecast by Country (2025-2030) & (M USD)
Table 152. Asia Pacific Non-Insulin Therapies for Diabetes Sales Forecast by Region (2025-2030) & (K Units)
Table 153. Asia Pacific Non-Insulin Therapies for Diabetes Market Size Forecast by Region (2025-2030) & (M USD)
Table 154. South America Non-Insulin Therapies for Diabetes Sales Forecast by Country (2025-2030) & (K Units)
Table 155. South America Non-Insulin Therapies for Diabetes Market Size Forecast by Country (2025-2030) & (M USD)
Table 156. Middle East and Africa Non-Insulin Therapies for Diabetes Consumption Forecast by Country (2025-2030) & (Units)
Table 157. Middle East and Africa Non-Insulin Therapies for Diabetes Market Size Forecast by Country (2025-2030) & (M USD)
Table 158. Global Non-Insulin Therapies for Diabetes Sales Forecast by Type (2025-2030) & (K Units)
Table 159. Global Non-Insulin Therapies for Diabetes Market Size Forecast by Type (2025-2030) & (M USD)
Table 160. Global Non-Insulin Therapies for Diabetes Price Forecast by Type (2025-2030) & (USD/Unit)
Table 161. Global Non-Insulin Therapies for Diabetes Sales (K Units) Forecast by Application (2025-2030)
Table 162. Global Non-Insulin Therapies for Diabetes Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Non-Insulin Therapies for Diabetes
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Non-Insulin Therapies for Diabetes Market Size (M USD), 2019-2030
Figure 5. Global Non-Insulin Therapies for Diabetes Market Size (M USD) (2019-2030)
Figure 6. Global Non-Insulin Therapies for Diabetes Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Non-Insulin Therapies for Diabetes Market Size by Country (M USD)
Figure 11. Non-Insulin Therapies for Diabetes Sales Share by Manufacturers in 2023
Figure 12. Global Non-Insulin Therapies for Diabetes Revenue Share by Manufacturers in 2023
Figure 13. Non-Insulin Therapies for Diabetes Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Non-Insulin Therapies for Diabetes Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Non-Insulin Therapies for Diabetes Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Non-Insulin Therapies for Diabetes Market Share by Type
Figure 18. Sales Market Share of Non-Insulin Therapies for Diabetes by Type (2019-2024)
Figure 19. Sales Market Share of Non-Insulin Therapies for Diabetes by Type in 2023
Figure 20. Market Size Share of Non-Insulin Therapies for Diabetes by Type (2019-2024)
Figure 21. Market Size Market Share of Non-Insulin Therapies for Diabetes by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Non-Insulin Therapies for Diabetes Market Share by Application
Figure 24. Global Non-Insulin Therapies for Diabetes Sales Market Share by Application (2019-2024)
Figure 25. Global Non-Insulin Therapies for Diabetes Sales Market Share by Application in 2023
Figure 26. Global Non-Insulin Therapies for Diabetes Market Share by Application (2019-2024)
Figure 27. Global Non-Insulin Therapies for Diabetes Market Share by Application in 2023
Figure 28. Global Non-Insulin Therapies for Diabetes Sales Growth Rate by Application (2019-2024)
Figure 29. Global Non-Insulin Therapies for Diabetes Sales Market Share by Region (2019-2024)
Figure 30. North America Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Non-Insulin Therapies for Diabetes Sales Market Share by Country in 2023
Figure 32. U.S. Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Non-Insulin Therapies for Diabetes Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Non-Insulin Therapies for Diabetes Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Non-Insulin Therapies for Diabetes Sales Market Share by Country in 2023
Figure 37. Germany Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Non-Insulin Therapies for Diabetes Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Non-Insulin Therapies for Diabetes Sales Market Share by Region in 2023
Figure 44. China Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Non-Insulin Therapies for Diabetes Sales and Growth Rate (K Units)
Figure 50. South America Non-Insulin Therapies for Diabetes Sales Market Share by Country in 2023
Figure 51. Brazil Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Non-Insulin Therapies for Diabetes Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Non-Insulin Therapies for Diabetes Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Non-Insulin Therapies for Diabetes Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Non-Insulin Therapies for Diabetes Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Non-Insulin Therapies for Diabetes Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Non-Insulin Therapies for Diabetes Market Share Forecast by Type (2025-2030)
Figure 65. Global Non-Insulin Therapies for Diabetes Sales Forecast by Application (2025-2030)
Figure 66. Global Non-Insulin Therapies for Diabetes Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Non-Insulin Therapies for Diabetes
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Non-Insulin Therapies for Diabetes Market Size (M USD), 2019-2030
Figure 5. Global Non-Insulin Therapies for Diabetes Market Size (M USD) (2019-2030)
Figure 6. Global Non-Insulin Therapies for Diabetes Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Non-Insulin Therapies for Diabetes Market Size by Country (M USD)
Figure 11. Non-Insulin Therapies for Diabetes Sales Share by Manufacturers in 2023
Figure 12. Global Non-Insulin Therapies for Diabetes Revenue Share by Manufacturers in 2023
Figure 13. Non-Insulin Therapies for Diabetes Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Non-Insulin Therapies for Diabetes Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Non-Insulin Therapies for Diabetes Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Non-Insulin Therapies for Diabetes Market Share by Type
Figure 18. Sales Market Share of Non-Insulin Therapies for Diabetes by Type (2019-2024)
Figure 19. Sales Market Share of Non-Insulin Therapies for Diabetes by Type in 2023
Figure 20. Market Size Share of Non-Insulin Therapies for Diabetes by Type (2019-2024)
Figure 21. Market Size Market Share of Non-Insulin Therapies for Diabetes by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Non-Insulin Therapies for Diabetes Market Share by Application
Figure 24. Global Non-Insulin Therapies for Diabetes Sales Market Share by Application (2019-2024)
Figure 25. Global Non-Insulin Therapies for Diabetes Sales Market Share by Application in 2023
Figure 26. Global Non-Insulin Therapies for Diabetes Market Share by Application (2019-2024)
Figure 27. Global Non-Insulin Therapies for Diabetes Market Share by Application in 2023
Figure 28. Global Non-Insulin Therapies for Diabetes Sales Growth Rate by Application (2019-2024)
Figure 29. Global Non-Insulin Therapies for Diabetes Sales Market Share by Region (2019-2024)
Figure 30. North America Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Non-Insulin Therapies for Diabetes Sales Market Share by Country in 2023
Figure 32. U.S. Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Non-Insulin Therapies for Diabetes Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Non-Insulin Therapies for Diabetes Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Non-Insulin Therapies for Diabetes Sales Market Share by Country in 2023
Figure 37. Germany Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Non-Insulin Therapies for Diabetes Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Non-Insulin Therapies for Diabetes Sales Market Share by Region in 2023
Figure 44. China Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Non-Insulin Therapies for Diabetes Sales and Growth Rate (K Units)
Figure 50. South America Non-Insulin Therapies for Diabetes Sales Market Share by Country in 2023
Figure 51. Brazil Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Non-Insulin Therapies for Diabetes Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Non-Insulin Therapies for Diabetes Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Non-Insulin Therapies for Diabetes Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Non-Insulin Therapies for Diabetes Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Non-Insulin Therapies for Diabetes Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Non-Insulin Therapies for Diabetes Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Non-Insulin Therapies for Diabetes Market Share Forecast by Type (2025-2030)
Figure 65. Global Non-Insulin Therapies for Diabetes Sales Forecast by Application (2025-2030)
Figure 66. Global Non-Insulin Therapies for Diabetes Market Share Forecast by Application (2025-2030)
